New Zealand approves Pfizer-BioNtech’s COVID-19 Vaccine

Published by admin on

New Zealand COVID-19 vaccine

The New Zealand Government has granted formal approval for use of Pfizer and BioNTech’s Covid-19 vaccine as a critical step to ensure the vaccine is safe and effective.

The Pfizer and BioNTech’s COVID-19 vaccine has been granted approval in New Zealand. The Medicines and Medical Devices Safety Authority, Medsafe, gave provisional approval for the vaccine.

The government is continuing to go by the book and has carefully considered the ‘decision to use’ the Pfizer / BioNTech vaccine as part of our nationwide program.

As part of our portfolio, we have secured up to 750,000 courses of the Pfizer Covid-19 vaccine through an Advance Purchase Agreement, and we are seeking a further small allocation through the COVAX Facility.

We will start vaccinating our border workers within days of arrival and then the people they live with

Covid-19 Response Minister Chris Hipkins

Last October, Pfizer and BioNTech entered an agreement with the New Zealand government to supply 1.5 million doses of their Covid-19 vaccine.

New Zealand plans to prioritize nurses, cleaners, security staff, customs and border officials, airline staff and hotel workers.

In addition Medsafe has initiated engagement with Novavax, the American vaccine development company.

There are still huge logistical challenges associated with the distribution of the Pfizer vaccine which requires ultra cold storage during transportation.

Article first published on Pharmaceutical Technology


Leave a Reply

Your email address will not be published. Required fields are marked *